In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Karuna Therapeutics (KRTX – Research Report), with a price target of $260.00. The company’s shares closed yesterday at $261.31.
According to TipRanks, Matteis is a 4-star analyst with an average return of 10.0% and a 50.99% success rate. Matteis covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, BioMarin Pharmaceutical, and Avadel Pharmaceuticals.
Currently, the analyst consensus on Karuna Therapeutics is a Strong Buy with an average price target of $241.07, a -7.75% downside from current levels. In a report released on August 10, Wells Fargo also maintained a Buy rating on the stock with a $264.00 price target.
KRTX market cap is currently $7.75B and has a P/E ratio of -38.13.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KRTX in relation to earlier this year. Earlier this month, James Healy, a Director at KRTX bought 32,500.00 shares for a total of $520,000.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.
Read More on KRTX:
- Stifel Nicolaus Sticks to Its Buy Rating for Power Integrations (POWI)
- Stifel Nicolaus Sticks to Its Hold Rating for Kornit Digital (KRNT)
- Stifel Nicolaus Keeps Their Hold Rating on Watts Water Technologies (WTS)
- Stifel Nicolaus Sticks to Its Buy Rating for ITT (ITT)
- Analysts’ Top Technology Picks: Omnicell (OMCL), Workiva (WK)